Due to the previously described immune modulatory effects of TGFβ-specific T cells on fibroblasts in the tumor [10, 11], CAFs acquired an increased IL-6-secreting profile following treatment with the TGFβ vaccine. This evidence concerns the gene TGFB1 and neoplasm.